Excellent! I now have the core diabetes theory from Harrison's 22E. Let me compile a comprehensive response using all the information gathered.
Diabetes Mellitus - Reference Theory (Dr. Archith Boloor / Harrison's 22E)
Dr. Archith Boloor is Associate Professor of Medicine at Kasturba Medical College (KMC), Mangalore (Manipal Academy of Higher Education). He is a prolific author of several medical textbooks including:
- An Insider's Guide to Clinical Medicine (3rd Ed, 2026) - Jaypee Brothers
- Exam Preparatory Manual for Undergraduates - Medicine (5th Ed, 2026)
- Mastering MCQs in Medicine for NEET PG (2025)
- ABC of ECG (2024)
His YouTube lecture on Diabetes-1 covers: definition, classification, and differences between Type 1 and Type 2 DM.
The reference textbook he follows (standard for Indian medical education) is Harrison's Principles of Internal Medicine. Below is the complete theory based on Harrison's 22nd Edition (2025):
DIABETES MELLITUS - Complete Theory
Definition
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia. Several distinct types of DM are caused by a complex interaction of genetics and environmental factors. Factors contributing to hyperglycemia include:
- Reduced insulin secretion
- Decreased glucose utilization
- Increased glucose production
(Harrison's Principles of Internal Medicine 22E, p. 3227)
Classification (Table 415-1 - Harrison's)
DM is classified on the basis of the pathogenic process leading to hyperglycemia:
| Type | Mechanism |
|---|
| Type 1 DM | Autoimmune destruction of beta cells → absolute insulin deficiency |
| Type 2 DM | Insulin resistance + impaired insulin secretion + increased hepatic glucose production |
| MODY (Maturity Onset Diabetes of the Young) | Single-gene defects |
| Gestational DM (GDM) | Glucose intolerance first identified in pregnancy |
| Other specific types | Pancreatic disease, drug-induced, endocrinopathies, etc. |
Prediabetes:
- Impaired Fasting Glucose (IFG): FPG 100-125 mg/dL
- Impaired Glucose Tolerance (IGT): 2-hr OGTT 140-199 mg/dL
- HbA1c 5.7-6.4%
Diagnostic Criteria (ADA 2024)
| Test | Normal | Prediabetes | Diabetes |
|---|
| Fasting Plasma Glucose (FPG) | <100 mg/dL | 100-125 mg/dL | ≥126 mg/dL |
| 2-hr OGTT (75g) | <140 mg/dL | 140-199 mg/dL | ≥200 mg/dL |
| HbA1c | <5.7% | 5.7-6.4% | ≥6.5% |
| Random plasma glucose (with symptoms) | - | - | ≥200 mg/dL |
Type 1 Diabetes Mellitus
Pathophysiology:
- Autoimmune destruction of pancreatic beta cells
- Genetic susceptibility (HLA-DR3, HLA-DR4 alleles)
- Environmental triggers (viral infections, dietary factors)
- Results in absolute insulin deficiency
- Three stages defined by autoantibodies against pancreatic beta cell antigens
Clinical Features:
- Young age of onset (typically <30 years)
- Lean body habitus
- Polyuria, polydipsia, polyphagia, weight loss
- Prone to Diabetic Ketoacidosis (DKA)
- Requires exogenous insulin for survival
Type 2 Diabetes Mellitus
Pathophysiology:
Type 2 DM results from a progressive decline in insulin secretion, superimposed on a background of insulin resistance.
-
Insulin resistance: Glucose utilization is 30-60% lower than in non-diabetic individuals. Insulin receptor levels and tyrosine kinase activity in skeletal muscle are reduced.
-
Beta cell failure: As insulin resistance increases, the pancreas compensates by increasing insulin secretion. Eventually beta cells fail → frank hyperglycemia.
-
Adipokine dysregulation: Obesity (especially visceral fat) increases circulating free fatty acids, TNF-α, IL-6, resistin, and reduces adiponectin - all worsening insulin resistance.
-
Metabolic inflammation: Lipid accumulation in skeletal myocytes → impaired mitochondrial oxidative phosphorylation → reactive oxygen species → low-grade metabolic inflammation.
(Harrison's 22E, p. 3245)
Screening Criteria for Type 2 DM (ADA 2024)
Test adults of any age who are overweight/obese (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Indians) with one of the following risk factors:
- Family history of diabetes (parent or sibling)
- Race/ethnicity (South Asian, African American, Latino, etc.)
- Hypertension (BP ≥130/80 mmHg)
- HDL <35 mg/dL and/or TG >250 mg/dL
- PCOS or acanthosis nigricans
- History of cardiovascular disease
- Physical inactivity
- IFG, IGT, or HbA1c 5.7-6.4% → screen annually
- GDM history → screen every 3 years
- Age ≥35 years without risk factors → screen every 3 years
Insulin Preparations (for Type 1 DM management)
| Preparation | Onset | Peak | Duration |
|---|
| Rapid-acting (Aspart, Glulisine, Lispro) | <15 min | 0.5-1.5 h | 3-5 h |
| Short-acting (Regular) | 0.5-1 h | 2-3 h | 4-8 h |
| Intermediate (NPH) | 2-4 h | 4-10 h | 10-16 h |
| Long-acting (Glargine, Detemir) | 1-4 h | Peakless | 20-24 h |
| Ultra long-acting (Degludec) | 1-9 h | Peakless | >42 h |
YouTube Lecture Reference
Dr. Archith Boloor's own lecture covering this topic:
Learning outcomes from his lecture:
- Define diabetes mellitus
- Classify diabetes
- List the differences between Type 1 and Type 2 DM
- Pathophysiology of DM
Recommended Books by Dr. Archith Boloor
- An Insider's Guide to Clinical Medicine (3rd Ed, 2026) - Jaypee Brothers - available here
- Exam Preparatory Manual for Undergraduates - Medicine (5th Ed, 2026)
- Mastering MCQs in Medicine for NEET PG (2025)
For the full reference theory paper on DM as per his teaching, refer to Harrison's Principles of Internal Medicine 22E, Chapter 415 (pp. 3227-3292) - which is the standard reference textbook used in Indian medical colleges including KMC Mangalore.